We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ACN:NYSEAccenture plc Analysis

Data as of 2026-05-17 - not real-time

$168.82

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Accenture (ACN) trades at roughly $168, well below its DCF fair value of $373 and the industry PE average of 38.6, indicating a substantial valuation gap. Fundamentally, the company delivers solid profitability with a 10.6% profit margin, 32% gross margin, and a healthy free cash flow of $12.2 B, supporting its 3.86% dividend yield and a payout ratio just over 50%. Technical indicators are mixed: the 20‑day SMA (≈$178) sits above the current price, the RSI is at 38.6 suggesting limited upside momentum, and the MACD remains bearish, while volume is increasing and the stock is holding above the identified support of $155.8. Recent news highlights strategic AI and compliance investments (Iridius) and high‑profile partnerships (WTA, Google Cloud), underscoring growth potential despite a cautious earnings outlook.
Given the pronounced undervaluation, strong cash generation, and expanding AI‑driven service portfolio, the stock presents a compelling entry point for investors willing to navigate short‑term bearish technical signals in favor of medium‑ to long‑term upside toward the analyst median target of $248.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and RSI indicating limited upside momentum
  • Current price above immediate support level
  • Attractive dividend yield providing downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation upside versus DCF fair value
  • Strategic AI and cloud partnerships expanding revenue streams
  • Strong cash flow and sustainable dividend supporting total return

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term demand for digital transformation and AI services
  • Robust balance sheet with low debt‑to‑equity and high ROE
  • Consistent dividend growth reinforcing shareholder loyalty

Key Metrics & Analysis

Financial Health

Revenue Growth8.30%
Profit Margin10.61%
P/E Ratio13.8
ROE24.76%
ROA11.16%
Debt/Equity25.47
P/B Ratio3.3
Op. Cash Flow$13.1B
Free Cash Flow$12.2B
Industry P/E38.6

Technical Analysis

TrendBearish
RSI38.6
Support$155.82
Resistance$199.58
MA 20$177.93
MA 50$189.36
MA 200$235.05
MACDBearish
VolumeIncreasing
Fear & Greed Index88.52

Valuation

Fair Value$372.89
Target Price$247.55
Upside/Downside46.63%
GradeUndervalued
TypeBlend
Dividend Yield3.86%

Risk Assessment

Beta0.72
Volatility43.97%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.